Brainaurora-b
Brainaurora-b (6681.HK) Stock Overview
Explore Brainaurora-b’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
7.1B
P/E Ratio
-23.22
EPS (TTM)
$-0.17
ROE
0.50%
6681.HK Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Brainaurora-b (6681.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 22.37, suggesting the stock is in an oversold condition. Our forecasting models predict significant price movements, with a 12-month target of N/A.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -23.22 and a market capitalization of 7.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
BrainAurora Medical Technology Limited develops medical-grade digital therapy (DTx) products for cognitive impairment. The company offers the evaluation and intervention of cognitive impairments to treat vascular diseases, neurodegenerative diseases, psychological disorders, and child development deficiencies. It develops the Brain Function Information Management Platform software system, an evidence-based, medical-grade DTx product; Cognitive Ability Testing software; the Cognitive Ability Supplemental Screening and Assessment software; and the Dyslexia Supplemental Screening and Assessment software. The company was founded in 2012 and is based in Shaoxing, China.
Xiaoyi Wang
159
Room 1301, Building 3, Shaoxing
2025